Cao Richard Y, Zhang Ying, Feng Zhen, Liu Siyu, Liu Yifan, Zheng Hongchao, Yang Jian
CMVD Collaborative Program, Shanghai Xuhui Central Hospital, Fudan University, Shanghai, China.
School of Sport Kinesiology, Shanghai University of Sport, Shanghai, China.
Front Pharmacol. 2021 Dec 22;12:764994. doi: 10.3389/fphar.2021.764994. eCollection 2021.
The exacerbation of oxidative and inflammatory reactions has been involved in atherosclerotic cardiovascular diseases leading to morbidity and mortality worldwide. Discovering the underlying mechanisms and finding optimized curative approaches to control the global prevalence of cardiovascular diseases is needed. Growing evidence has demonstrated that gut microbiota is associated with the development of atherosclerosis, while berberine, a natural product exhibits antiatherogenic effects in clinical and pre-clinical studies, which implies a potential link between berberine and gut microbiota. In light of these novel discoveries, evidence of the role of berberine in modulating atherosclerosis with a specific focus on its interaction with gut microbiota is collected. This review synthesizes and summarizes antioxidant and anti-inflammatory effects of berberine on combating atherosclerosis experimentally and clinically, explores the interaction between berberine and intestinal microbiota comprehensively, and provides novel insights of berberine in managing atherosclerotic cardiovascular diseases via targeting the gut-heart axis mechanistically. The phenomenon of how berberine overcomes its weakness of poor bioavailability to conduct its antiatherogenic properties is also discussed and interpreted in this article. An in-depth understanding of this emerging area may contribute to identifying therapeutic potentials of medicinal plant and natural product derived pharmaceuticals for the prevention and treatment of atherosclerotic cardiovascular diseases in the future.
氧化和炎症反应的加剧与动脉粥样硬化性心血管疾病相关,这些疾病在全球范围内导致发病和死亡。需要发现潜在机制并找到优化的治疗方法来控制心血管疾病的全球流行率。越来越多的证据表明,肠道微生物群与动脉粥样硬化的发展有关,而黄连素作为一种天然产物,在临床和临床前研究中显示出抗动脉粥样硬化作用,这意味着黄连素与肠道微生物群之间存在潜在联系。鉴于这些新发现,收集了黄连素在调节动脉粥样硬化中作用的证据,特别关注其与肠道微生物群的相互作用。这篇综述综合并总结了黄连素在实验和临床中对抗动脉粥样硬化的抗氧化和抗炎作用,全面探讨了黄连素与肠道微生物群之间的相互作用,并通过靶向肠-心轴机制为黄连素在管理动脉粥样硬化性心血管疾病方面提供了新的见解。本文还讨论并解释了黄连素如何克服其生物利用度差的弱点以发挥其抗动脉粥样硬化特性的现象。对这一新兴领域的深入理解可能有助于未来识别药用植物和天然产物衍生药物在预防和治疗动脉粥样硬化性心血管疾病方面的治疗潜力。